Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.
Back to dashboard
Company Information
About this company
Key people
Quang X. Pham
Chairman of the Board, Chief Executive Officer
John P. Sharp
Interim Chief Financial Officer
Jeffrey Cole
Chief Operating Officer
James J. Ferguson
Chief Medical Officer
Lee Golden
Independent Director
John R. Murphy
Independent Director
Glynn Wilson
Independent Director
Click to see more
Key facts
- Shares in issue3.10m
- EPICCVKD
- ISINUS1276362076
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$6.51m
- Employees5
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.